Smith+Nephew’s IODOSORB™ Range

Shown more than twice as likely to heal wounds than standard care

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a systematic review and meta-analysis of comparative trials to determine the efficacy of its IODOSORB 0.9% Cadexomer Iodine Range* on chronic wounds versus standard care specific to the wound type.1

The review found that wounds were more than twice as likely to completely heal with IODOSORB Range than with standard care, and significantly greater reductions in wound area** were observed after 8 weeks of treatment versus standard care.

Use of IODOSORB Range helped reduce barriers to healing such as exudate, slough, pus, debris and bacteria, significantly reducing wound area** and increasing the chance of healing chronic wounds compared with standard care.1 Venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and pressure ulcers were included in the study.

“With the cost of chronic hard to heal wounds an estimated $3.9 billion in Canada, they can be a major burden on patient quality of life, healthcare resources and budgets,” said Dr. Kevin Woo, PhD, RN, Associate Professor, Queen’s School of Nursing, University of Toronto, Canada. “The data demonstrate consistent positive outcomes [IODOSORB] has on chronic stalled wounds through the removal of barriers that impede wound healing.”

The review included 13 studies comparing IODOSORB Dressings with standard care, summarising the clinical evidence supporting IODOSORB Dressings in wound bed preparation. In addition to patient comorbidities, there were a number of local factors that could act as barriers to wound healing. These included excessive exudate, cellular debris/pus/slough, and the presence of biofilm or infection.1

IODOSORB Dressing is a unique topical antimicrobial with dual-action, offering the benefits of a broad-spectrum, sustained-activity antimicrobial agent in combination with desloughing and fluid-handling properties, making it effective against biofilm in vitro and in vivo.2-28


  1. Woo K, Dowsett C, Costa B, Ebohon S, Woodmansey EJ, Malone M. Efficacy of topical cadexomer iodine treatment in chronic wounds: Systematic review and meta-analysis of comparative clinical trials. Int Wound J. 2021;[Epub ahead of print].
  2. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB/IODOFLEX Dressings. Internal Report. DS/17/365/R.
  3. Skog E. et al. A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Br. J. Dermatol. 1983;109:77–83
  4. Moberg S, Hoffman L, Grennert ML, Holst A. A randomized trial of cadexomer iodine in decubitus ulcers. J Am Geriatr Soc. 1983;31(8):462-465.
  5. Harcup JW, Saul PA. A study of the effect of cadexomer iodine in the treatment of venous leg ulcers. Br J Clin Pract. 1986;40(9):360-364.
  6. Hillström L. Iodosorb compared to standard treatment in chronic venous leg ulcers–a multicenter study. Acta Chir Scand Suppl. 1988;544:53-56.
  7. Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of cadexomer iodine against Staphylococcus aureus biofilm in vivo and in vitro using confocal laser scanning microscopy. J Dermatol. 2004;31(7):529-534.
  8. Zhou LH, Nahm WK, Badiavas E, Yufit T, Falanga V. Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol. 2002;146(3):365-374.
  9. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Powder. Internal Report. DS/17/363/R.
  10. Smith + Nephew 2017. Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Ointment/Gel. DS/17/364/R.
  11. Perstorp Pharmaceuticals. Iodine release from CADEX, iodocoat and U pasta. Smith & Nephew Data on file #091101. (2009).
  12. Troëng T, Skog E, Arnesjö B, Gjöres JE, Bergljung L, Gundersen J, E. A. A randomised multicentre trial to compare the efficacy of cadexomer iodine and standard treatment in the management of chronic venous ulcers in out patients. in Cadexomer Iodine, (eds. Fox, J. & Fisher, H.) 43–50 (Schattauer Verlag, 1983).
  13. Holloway GA Jr, Johansen KH, Barnes RW, Pierce GE. Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med. 1989;151(1):35-38.
  14. Hansson C. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. Cadexomer Iodine Study Group. Int J Dermatol. 1998;37(5):390-396.
  15. Ormiston MC, Seymour MT, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. Br Med J (Clin Res Ed). 1985;291(6491):308-310. doi:10.1136/bmj.291.6491.308
  16. Smith & Nephew 2008. IODOFLEX dressings against a variety of micro-organisms grown in single and mixed species biofilms. Internal Report. 0804006.
  17. Smith & Nephew 2008. IODOFLEX dressings – disruption of a variety of micro-organisms grown in pre-established single and mixed species biofilms. Internal Report. 0804007.
  18. Oates JL, Phillips CD, Wolcott R, Woodmansey E. Effect of a Cadexomer Iodine Wound Dressing on a Chronic Wound Multi-Species Biofilm Model with Comparison to a Silver Hydrofiber Antibiofilm Dressing. in SAWC Atlanta 1 (2016).
  19. Schierle CF, De la Garza M, Mustoe TA, Galiano RD. Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair Regen. 2009;17(3):354-359.
  20. Wolcott RD, Rhoads DD, Bennett ME, et al. Chronic wounds and the medical biofilm paradigm. J Wound Care. 2010;19(2):45-53.
  21. Lindsay G, Latta D, Lyons KGB. A study in general practice of the efficacy of cadexomer iodine in venous leg ulcers treated on alternate days. Acta Ther. 12, 141–148 (1986).
  22. Schwartz JA, Lantis JC 2nd, Gendics C, Fuller AM, Payne W, Ochs D. A prospective, non comparative, multicenter study to investigate the effect of cadexomer iodine on bioburden load and other wound characteristics in diabetic foot ulcers. Int Wound J. 2013;10(2):193-199.
  23. Smith + Nephew 2018. Antimicrobial activity of IODOSORB range against a broad spectrum of wound pathogens. Internal Report. 1801001
  24. Smith + Nephew 2007. An evaluation of the use of IODOSORB ointment and dressing in the management of chronic exuding wounds. Internal Report. SR/CE/027/IOD.
  25. Smith & Nephew 2018. Antimicrobial activity of IODOSORB range in a 3 day repeat challenge model. Internal Report. 1801002.
  26. Smith + Nephew 2018.Release of Iodine from IODOSORB Powder into 0.9% saline solution over a three day period. Internal Report. DS/18/024/R.
  27. Smith + Nephew 2018.Release of IODOSORB Ointment / Gel into 0.9% saline solution over a three day period. Internal Report. DS/18/025/R.
  28. Smith + Nephew 2018.Release of Iodine from IODOSORB / IODOFLEX Dressing into 0.9% saline solution over a three day period. Internal Report. DS/18/026/R.
Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy